Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review
- 170 Downloads
The aim of the review is to examine the role of growth factors and cytokines in the management of Diabetic Foot Ulcers, such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and Insulin like growth factor (IGF). Taking this a step further, the role of Hypoxia-inducible factors (HIFs), Transforming growth factor beta 1 (TGF-β-1) and other growth factors have also been examined, with regard to the treatment of diabetic foot ulcers. The roles of these above-mentioned growth cytokines have been analyzed by studying various scholastic articles. The complete process of wound healing is implemented and regulated by numerous cytokines and human growth factors. The findings of the study indicate that wound healing of diabetic foot ulcers is a complex and extremely challenging biological and molecular process that involves coordinated efforts of multiple cell types. The therapeutic effects of various growth factors in the clinical management of wounds are chronic venous ulcers, pressure ulcers, and diabetic foot ulcers. It has been concluded that altercations of various cytokines are found in patients enduring diabetic foot ulcers. In a similar way, changes in the level of cytokines are also found in patients suffering from other diabetic complications such as diabetic nephropathy, retinopathy, and neuropathy. Subsequently, the diabetic wound healing process can be accelerated by regulating the levels of the cytokines.
KeywordsCytokines Diabetic ulcers Growth factors Molecular process Wound healing Mechanism Vascular endothelial growth factor Insulin
The author is very thankful to all the associated personnel in any reference that contributed in/for the purpose of this research.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.World Health Organization. Accessible at http://www.who.int/diabetes/en/, retrieved on 7 Nov 2018.
- 5.Pallela SR, Narahari P. A study to find the causes of diabetic foot infections in a selected community. International Surgery Journal. 2017;4(7):2153–56. https://doi.org/10.18203/2349-2902.isj20172576.
- 6.American Diabetic Association. (2018). Accessible at: http://www.diabetes.org/diabetes-basics/statistics/. Retrieved on 11 Nov 2018.
- 9.Omanakuttan A, Nambiar J, Harris RM, Bose C, Pandurangan N, Varghese RK, et al. Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9. Molecular Pharmacology. 2012: Mol-112. https://doi.org/10.1124/mol.112.079020.
- 14.Heldin C-H, Rönnstrand L. The platelet-derived growth factor receptor. In: Moudgil VK, editor. Receptor phosphorylation. Boca Raton: CRC Press; 1988. p. 149–62.Google Scholar
- 21.Braun AC. Bioresponsive delivery of anticatabolic and anabolic agents for muscle regeneration using bioinspired strategies. Available at https://opus.bibliothek.uni-wuerzburg.de/opus4-wuerzburg/frontdoor/deliver/index/docId/16904/file/Braun_Alexandra_Bioresponsive_delivery.pdf
- 32.Robson MC, Payne WG. Growth factor therapy to aid wound healing. Basic and Clinical Dermatology. 2005;33:491.Google Scholar
- 38.Liu L, Chen B, Zhang X, Tan L, Wang DW. Increased Cathepsin D correlates with clinical parameters in newly diagnosed type 2 diabetes. Dis Markers. 2017;2017:1–6.Google Scholar
- 39.Nowak C, Sundström J, Gustafsson S. Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes. 2016;65:276–84.Google Scholar
- 44.Gruden G, Bruno G, Chaturvedi N. Prospective complications study group. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study. A novel circulating marker for diabetic neuropathy. Diabetes. 2008;57:1966–70. https://doi.org/10.2337/db08-0009.CrossRefGoogle Scholar
- 46.Zubair M, Ahmad J. Plasma heat shock proteins (HSPs) 70 and 47 levels in diabetic foot and its possible correlation with clinical variables in a north Indian tertiary care hospital. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 2015;9:237–43. https://doi.org/10.1016/j.dsx.2015.02.015.CrossRefGoogle Scholar
- 51.Foy Y, Li J, Kirsner R, Eaglstein W. Analysis of fibroblast defects in extracellular matrix. J Am Acad Dermatol. 2004;50(3):P168.Google Scholar
- 54.Ching YH, Sutton TL, Pierpont YN, Robson MC, Payne WG. The use of growth factors and other humoral agents to accelerate and enhance burn wound healing. Eplasty. 2011;11.Google Scholar
- 56.Bakker AD, Schrooten J, Van Cleynenbreugel T, Vanlauwe J, Luyten J, Schepers E, Dubruel P, Schacht E, Lammens J, Luyten FP. Quantitative screening of engineered implants in a long bone defect model in rabbits. Tissue Eng Part C: Methods. 2008;14(3):251–60. https://doi.org/10.1089/ten.tec.2008.0022.
- 62.Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Investig. 2007;117(5):1219–22.Google Scholar